Clinical Trials

Pancreatic Neoplasms

NCT05494580 2026-03-10

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Phase 1/2 Completed

29 enrolled

Gynecologic

Ovarian Neoplasms

NCT06719700 2026-03-03

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

47 enrolled

Phase 3 Not yet recruiting

Small Cell Lung Carcinoma

NCT07436741 2026-02-27

Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

106 enrolled

Pancreatic cancer, adult

NCT07272512 2025-12-19

ZSPAC-17

Phase 4 Recruiting

350 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT05472948 2025-12-17

Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma

36 enrolled

Appendiceal Neoplasms, Neoplasm Metastasis

NCT07279532 2025-12-12

Clinical Study of Adjuvant Surufatinib Therapy for Postoperative High-risk Neuroendocrine Tumors Based on the Ninth Edition of the AJCC Staging System

Phase 2 Active not recruiting

35 enrolled

Tumor-Agnostic

Neoplasms

NCT05481476 2025-09-04

Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer

32 enrolled

Pancreatic Neoplasms

NCT07086456 2025-07-25

Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05481463 2025-05-28

Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer

Phase 2 Completed

22 enrolled

Pancreatic Neoplasms

NCT05165407 2025-03-14

NESSIE

EndocrineNET

Neuroendocrine Tumors

NCT05218889 2024-12-31

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

Phase 1/2 Recruiting

90 enrolled

Phase 2 Active not recruiting

Pancreatic Neoplasms

NCT05652283 2024-11-27

Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

37 enrolled

Gynecologic

Ovarian Neoplasms

NCT06437353 2024-11-27

Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer

Phase 2 Active not recruiting

74 enrolled

Gynecologic

Ovarian Neoplasms

NCT06239532 2024-11-21

HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma

28 enrolled

Cholangiocarcinoma

NCT04922658 2024-07-31

Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer

60 enrolled

Advanced Non-Small Cell Lung Cancer

NCT06531291 2024-07-31

Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation

80 enrolled

Biliary Tract Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT05832892 2024-06-14

Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer

41 enrolled

Pancreatic Neoplasms

NCT06447636 2024-06-07

Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma

20 enrolled

Stomach Neoplasms

NCT06414915 2024-05-16

Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation

29 enrolled

NSCLC

NCT06375642 2024-04-19

A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC

Cholangiocarcinoma

NCT05926492 2024-04-17

A Clinical Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in Osteosarcoma

160 enrolled

Sarcoma

Osteosarcoma

NCT06255262 2024-02-13

Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Biliary Tract Neoplasms

NCT06158516 2023-12-06

A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors

100 enrolled

Adenoma, Islet Cell

NCT06134193 2023-11-18

Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer

41 enrolled

Carcinoma, Gallbladder Neoplasms, Cholangiocarcinoma

NCT05988372 2023-11-01

Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)

50 enrolled

Locally Advanced Pancreatic Cancer

NCT05989425 2023-08-14

Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer

32 enrolled

EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT05973968 2023-08-04

Surufatinib in G3 Neuroendocrine Tumors

Unknown

32 enrolled

EndocrineNET

Neuroendocrine Tumor Grade 3

NCT04653480 2023-07-17

Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC

61 enrolled

Colorectal Neoplasms

NCT05106777 2023-04-12

Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma

47 enrolled

Sarcoma

NCT05746728 2023-04-06

Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer

45 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05747729 2023-02-28

A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.

60 enrolled

Endocrine

Carcinoma, Neuroendocrine

NCT05627427 2022-11-25

Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy

EndocrineGastrointestinal

60 enrolled

Pancreatic Neoplasms, Carcinoma, Neuroendocrine

NCT04996771 2022-11-14

Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer

88 enrolled

Small Cell Lung Carcinoma

NCT05003037 2022-11-04

Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer

106 enrolled

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT05590572 2022-10-21

A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma

148 enrolled

Sarcoma

Osteosarcoma

NCT05186545 2022-09-02

An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer

63 enrolled

Breast

Breast Neoplasms

NCT05171439 2022-04-14

Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor Samples

6 enrolled

Carcinoma, Hepatocellular

NCT05282433 2022-03-16

Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma

45 enrolled

Carcinoma, Hepatocellular

NCT05056116 2021-12-27

A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer

Phase NA Unknown

Biliary Tract Neoplasms

NCT05030246 2021-09-01

Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer

72 enrolled

Refractory Metastatic Digestive System Carcinoma

NCT04929652 2021-06-18

Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer

48 enrolled

Advanced Colorectal Cancer

NCT04910854 2021-06-02

Surufatinib in Recurrent/Metastatic Head and Neck Adenocarcinomas

27 enrolled

Head & Neck

Head and Neck Cancers - Salivary Gland

NCT04524884 2020-08-24

Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study